Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
17.07B
Market cap17.07B
Price-Earnings ratio
29.21
Price-Earnings ratio29.21
Dividend yield
Dividend yield
Average volume
1.27M
Average volume1.27M
High today
$274.89
High today$274.89
Low today
$265.76
Low today$265.76
Open price
$270.90
Open price$270.90
Volume
543.66K
Volume543.66K
52 Week high
$274.89
52 Week high$274.89
52 Week low
$160.86
52 Week low$160.86

Stock Snapshot

As of today, Ascendis Pharma A/S(ASND) shares are valued at $274.50. The company's market cap stands at 17.07B, with a P/E ratio of 29.21.

As of 2026-07-03, Ascendis Pharma A/S(ASND) stock has fluctuated between $265.76 and $274.89. The current price stands at $274.50, placing the stock +3.3% above today's low and -0.1% off the high.

The Ascendis Pharma A/S(ASND)'s current trading volume is 543.66K, compared to an average daily volume of 1.27M.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $160.86 at its lowest and $274.89 at its peak.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $160.86 at its lowest and $274.89 at its peak.

ASND News

TipRanks 3d
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 3d
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial

Ascendis Pharma (ASND) announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP in children with acho...

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.